Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.
about
Controlling cytomegalovirus: helping the immune system take the leadPrevention and management of CMV-related problems after hematopoietic stem cell transplantation.Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor.Congenital cytomegalovirus infection manifesting as neonatal persistent pulmonary hypertension: report of two cases.Management of infectious complications in the hematopoietic stem cell transplant recipient.Pulmonary complications of solid organ and hematopoietic stem cell transplantation.Clinical applications for biomarkers of acute and chronic graft-versus-host disease.Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipientsVaccine strategies against human cytomegalovirus infection.Cytomegalovirus pneumonia in hematopoietic stem cell recipients.Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation.National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.Adoptive T cell therapy for the treatment of viral infections.Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation.Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen.Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis.Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
P2860
Q33820695-729C044F-DECA-464E-96C1-A502FD1725DCQ34785629-EDFDBFE8-0B41-4E86-8A6F-B7D97F051F32Q35063668-373DAAB7-2451-4D51-9958-DF3D2515F1D0Q35101631-4BE06892-4540-4EC7-993F-0917EA3EA837Q35675979-D71AA6D8-17E2-4DD4-9B05-914163C9137FQ35740698-71612464-2DC9-4B9C-AC03-0858FBFE20D4Q35767289-DDB13C51-517A-4C4B-855E-9F565E88792DQ35848175-5B79AE31-1431-4442-A7FE-66625853295DQ35922928-4616A760-A683-463A-B647-3E4FF926FD87Q36839736-E3D11743-3D3D-49D9-A99B-5D294D878DC8Q37179131-045E89C6-DFD8-47FB-91D7-B26A302FB935Q37203522-558A4B66-858A-4A39-B86F-350B241693D5Q37541299-53021873-9B02-4D68-BE61-C730EA8CF7F3Q38405199-4CCD0357-0889-4B9E-B98F-3094D4713435Q40272806-E5A58D39-A498-4233-B015-8441360925DCQ40895824-A7B075F1-F4C8-494E-99E8-E3AF8663DEA6Q44159632-138B40DB-EAFB-4DA1-A290-7049C991A079Q44557879-A402759E-2915-4546-BA20-3DEA0893BBBBQ44586690-0B5FC628-14C1-4FD2-BB75-D1FCB0275C1AQ44603440-45C2FA73-8A31-45DA-9F87-4C25E806D7ACQ44758867-6CA06224-C5FE-4391-A023-230ED8645E3CQ46693840-31B47E43-EA9F-41D7-99C9-058364137581Q53807644-144A8552-D288-4DC7-A78F-17188C0BF1E5
P2860
Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Current antiviral strategies f ...... ients: prevention and therapy.
@ast
Current antiviral strategies f ...... ients: prevention and therapy.
@en
Current antiviral strategies f ...... ients: prevention and therapy.
@nl
type
label
Current antiviral strategies f ...... ients: prevention and therapy.
@ast
Current antiviral strategies f ...... ients: prevention and therapy.
@en
Current antiviral strategies f ...... ients: prevention and therapy.
@nl
prefLabel
Current antiviral strategies f ...... ients: prevention and therapy.
@ast
Current antiviral strategies f ...... ients: prevention and therapy.
@en
Current antiviral strategies f ...... ients: prevention and therapy.
@nl
P2860
P1476
Current antiviral strategies f ...... ients: prevention and therapy.
@en
P2093
P2860
P304
P356
10.1034/J.1399-3062.1999.010305.X
P577
1999-09-01T00:00:00Z